Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00745368 |
Recruitment Status
:
Completed
First Posted
: September 3, 2008
Results First Posted
: October 10, 2012
Last Update Posted
: October 10, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Raltegravir | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 28 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Official Title: | Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | June 2011 |
Actual Study Completion Date : | June 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Raltegravir
Raltegravir 400 mg tablets twice daily
|
Drug: Raltegravir
400 mg tablets twice daily during duration of trial
|
- Raltegravir Male Genital Tract Concentration [ Time Frame: 8-10 hours after raltegravir dose ]
- Raltegravir Female Genital Tract Concentration [ Time Frame: 8-10 hours after raltegravir dose ]
- Male Paired Plasma Concentration [ Time Frame: 8-10 hours after raltegravir dose ]This sample was taken as close to the time of genital tract sample as possible
- Female Paired Plasma Concentration [ Time Frame: 8-10 hours after raltegravir dose ]This sample was taken as close to the time of genital tract sample as possible
- Male Time Since Last Dose [ Time Frame: 8-10 hours after raltegravir dose ]This measure describes the amount of time that expired between when the dose was administered and when the sample was taken
- Female Time Since Last Dose [ Time Frame: 8-10 hours after raltegravir dose ]This measure describes the amount of time that expired between when the dose was administered and when the sample was taken
- Male Genital Tract:Plasma Concentration Ratio [ Time Frame: 8-10 hours after raltegravir dose ]Units of raltegravir concentration for genital tract and plasma sample are ng/mL
- Female Genital Tract:Plasma Concentration Ratio [ Time Frame: 8-10 hours after raltegravir dose ]Units of raltegravir concentration for genital tract and plasma sample are ng/mL

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Documentation of blood seropositive for HIV based on self report and confirmed by ELISA and Western blot or detectable HIV RNA
- Stable anti-retroviral regimen for at least 3 weeks prior to enrollment
- Capable of giving informed consent
- Age 18 years and older
Exclusion Criteria:
- Neoplasms
- Women who are pregnant or nursing
- History or current evidence of any significant acute or chronic medical illness that in the opinion of the investigator would preclude the subject from safely participating in the study
- Current use of phenobarbital, phenytoin, or rifampin
- Any major surgery within 4 weeks of enrollment
- Blood transfusion within 4 weeks of enrollment
- Inability to tolerate oral medication
- Inability to tolerate venipuncture, venous access, or genital tract sampling
- History of recent (within 6 months) drug or alcohol abuse
- Evidence of organ dysfunction or any clinically significant deviation from normal in the medical history, physical examination, vital signs, and or clinical laboratory determinations that in the opinion of the investigator would preclude the subject from safely participating in the study
- Any other sound medical, psychiatric and or social reason for exclusion as determined by the investigator
- History of allergy to study medication or related compounds

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00745368
United States, New York | |
University of Rochester | |
Rochester, New York, United States, 14642 |
Responsible Party: | Robert Dicenzo, Adjunct Assistant Professor of Medicine, University of Rochester |
ClinicalTrials.gov Identifier: | NCT00745368 History of Changes |
Other Study ID Numbers: |
33113 |
First Posted: | September 3, 2008 Key Record Dates |
Results First Posted: | October 10, 2012 |
Last Update Posted: | October 10, 2012 |
Last Verified: | September 2012 |
Keywords provided by Robert Dicenzo, University of Rochester:
HIV Raltegravir pharmacokinetics Treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Raltegravir Potassium Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents HIV Integrase Inhibitors Integrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |